Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?
- First Online:
We hypothesized that combining pre- and postsynaptic quantitative information about the dopaminergic system would provide a higher diagnostic accuracy in the differential diagnosis of parkinsonism than specific striatal D2 receptor binding alone. Therefore, the aim of the study was to introduce new semi-quantitative parameters and evaluate their ability to discriminate between Parkinson’s disease (IPS) and non-idiopathic parkinsonian syndromes (non-IPS).
In 100 patients (69 IPS, 31 non-IPS), postsynaptic [123I]IBZM and presynaptic [123I]FP-CIT SPECT scans were evaluated by observer-independent techniques. The diagnostic performances of striatal dopamine transporter (DAT) and D2 receptor binding, their respective asymmetries, and a combination of pre- and postsynaptic asymmetry were evaluated with ROC analyses. A logistic regression model was generated combining factors to calculate the probability for each patient of belonging to either diagnostic group.
D2 receptor binding provided a sensitivity of 87.1% and a specificity of 72.5% with an area under the curve (AUC) of 0.866. The AUCs of other single parameters were lower than that of D2 binding. A gain of diagnostic power (p = 0.026) was reached with a model combining pre- and postsynaptic asymmetries and D2 binding (sensitivity 90.3%, specificity 73.9%, AUC 0.893).
The combination of quantitative parameters of presynaptic DAT and postsynaptic D2 receptor binding demonstrates superior diagnostic power in the differentiation of patients with IPS and non-IPS than the established approach based on D2 binding alone. Striatal D2 receptor binding and the combination of DAT and IBZM binding asymmetries are the factors contributing most in separating these diagnostic groups.
KeywordsQuantitative evaluation [123I]IBZM Automatic data processing Asymmetry
- 4.Quinn N. Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989;Suppl:78–89Google Scholar
- 30.Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24.PubMedGoogle Scholar
- 32.Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, et al. Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 1998;245:14–20.CrossRefPubMedGoogle Scholar